Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dexlansoprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP4A known ✓ | P20648 | 4/20 | 0.61 |
| ▸ | ATP4B known ✓ | P51164 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | WDR5 | P61964 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | ENGASE | Q8NFI3 | 3/20 | 0.61 |
| ▸ | SARM1 | Q6SZW1 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | ATP1A1 | P05023 | 3/20 | 0.61 |
| ▸ | ATP1B1 | P05026 | 3/20 | 0.61 |
| ▸ | ATP1A3 | P13637 | 3/20 | 0.61 |
| ▸ | ATP1B2 | P14415 | 3/20 | 0.61 |
| ▸ | ATP1A2 | P50993 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexlansoprazole SCHEMBL29950208 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29353345 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29750802 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL8597994 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL29353881 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL1559598 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL29358567 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Dexlansoprazole SCHEMBL44975 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22366 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 | |
| Lansoprazole SCHEMBL22365 | 1.00 | CYP2C9 (0.63) | CYP2C9NPC1RAB9ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117741011-A | Analysis method for separating enantiomer of prazoles proton pump inhibitor in human plasma by chiral liquid chromatography tandem mass spectrometry | 苏州海科医药技术有限公司 | 2024-03-22 | — | — | CN | claimed |
| US-20260097026-A1 | INHIBITION OF AORTIC VALVE CALCIFICATION | ZABIRNYK ARSENII (NO) | 2026-04-09 | — | — | US | disclosed |
| EP-4598528-A1 | INHIBITION OF AORTIC VALVE CALCIFICATION | Zabirnyk, Arsenil (NO) | 2025-08-13 | — | — | EP | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| WO-2024075017-A1 | INHIBITION OF AORTIC VALVE CALCIFICATION | ZABIRNYK ARSENII (NO) | 2024-04-11 | — | — | WO | disclosed |
| CN-117482106-A | Compound lansoprazole preparation | 康普药业股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-113358768-B | Method for simultaneously detecting levorotatory lansoprazole and dextrorotatory lansoprazole in human plasma by HPLC-MS/MS combination | 南京一诺医药科技有限公司 | 2022-12-23 | — | — | CN | disclosed |
| US-11491147-B2 | Combination drug therapy reduces PARP-1 related DNA repair and increases the efficacy of genotoxic agents | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2022-11-08 | — | — | US | disclosed |
| CN-108794450-B | Method for preparing amorphous dexlansoprazole | 浙江恒康药业股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ATP4A 4530/4885ATP4B 4729/4885CYP2C9 3805/4885 |
| US-20260097026-A1 | INHIBITION OF AORTIC VALVE CALCIFICATION | ATP2C1, ATP1A3, ATP2A3 | ATP4A 16/4885ATP4B 13/4885CYP2C9 197/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | ATP4A 4530/4885ATP4B 4729/4885CYP2C9 3805/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | ATP4A 4112/4885ATP4B 4694/4885CYP2C9 3606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.